Close Menu

More articles about Research & Discovery

The investment bank gave a price target of $3.33 per share for Aspira, which focuses on women's health, and $11.97 for dermatology firm DermTech.

Shares of the Boulder, Colorado-based firm will begin trading on the Nasdaq today under ticker symbol "BDSX" at $18 per share.

The firms will conduct PacBio whole-genome sequencing on epilepsy patients to generate variant profiles that can help the development of diagnostic assays.

Researchers showed benefit from chemotherapy in patients classified as high risk by the test, independent of their EGFR mutation status.

The ELISA-based test, which has CE marking, uses protein signatures in blood to detect the onset of kidney disease in type 2 diabetics.

Other grant recipients include scientists from the University of Chicago, UCLA, UC Santa Barbara, and the University of Washington.

The company's recent license agreement with Abbott is part of its plan to move its Simoa technology into the clinic via partners in LDT and IVD development.

The new company will use Seer's Proteograph proteomic platform along with other omics data to develop and commercialize tests for cancer and other diseases.

IncellDx has been developing a test for cytokine storm-related cytokines, which it said are elevated in COVID-19 patients who experience long-term symptoms.

The Harvard University spinout uses a combination of proprietary probes, nanoarrays, and convection PCR to target a broad set of molecular biomarkers.

KidneyIntelX is designed to help assess the risk of progressive decline in kidney function in patients with type 2 diabetes and chronic kidney disease.

Mount Sinai researchers investigated four cytokine proteins and found that two of them were elevated in the serum samples of SARS-CoV-2 patients who fared the worst.

The company, which went public in June, has had to deal with issues with the US DOJ, and some private insurers. Its CEO's tenure at Sequenom was also marred by a scandal.

The company, formerly known as Vermillion, reported total revenues of $746,000 and product revenues of $743,000 with sales of 2,458 OVA1 tests.

The company said that it has priced a public offering of 2,651,108 shares of its common stock at $32 per share.

TargetCancer is activating two enrollment sites and setting up a remote consenting process so patients with rare cancers can be seen at local community hospitals.

The company posted Q2 revenues of $13.1 million, down from $13.5 million in Q2 2019 but above the consensus Wall Street estimate of $11.8 million.

Antelope is currently developing a urine-based at-home test for the sexually transmitted infections Chlamydia trachomatis and Neisseria gonorrhoeae.

Washington University researchers and a team including scientists from Eli Lilly independently identified a modified form of tau as a promising Alzheimer's marker.

The Oslo-based company plans to develop a test that can identify high-risk individuals based on an epigenetic signature.

Pages